Raymond James initiated coverage of Evommune (EVMN) with a Strong Buy rating and $40 price target The firm views 2026 as a “catalyst-rich year” for Evommune. The shares at current levels offer a “compelling” risk/reward portfolio with “multiple ways to win,” the analyst tells investors in a research note. Raymond James believes the company’s chronic spontaneous urticaria readout in the first half of 2026 will attract the greatest investor attention.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVMN:
- Evommune’s EVO756 Trial Targets High-Need Urticaria Market: What Investors Should Watch
- Evommune participates in a conference call with William Blair
- Evommune initiated with a Buy at H.C. Wainwright
- 3 ‘Strong Buy’ Stocks to Buy Now,12/30/2025, According to Top Analysts
- Evommune: Multiple 2026 Phase II Readouts and Novel Immunology Mechanisms Drive Compelling Buy-Rated Risk‑Reward